Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1319-1327

  Martins, Helen R ^a   Figueiredo, L M ^a   Valamiel silva, J C O ^a   Carneiro, C M ^a   Machado Coelho, G L L ^a   Vitelli Avelar, D M ^b   Bahia, M T ^a   Martins Filho, O A ^b   Macedo, A M ^c   Lana, M ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cure control; Genetic diversity; Mixed infection; Murine model

Indexed keywords

BENZNIDAZOLE; DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BLOOD CULTURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG MONITORING; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FEMALE; GENETIC VARIABILITY; HISTOPATHOLOGY; INTERMETHOD COMPARISON; LABORATORY TEST; MIXED INFECTION; MOUSE; NONHUMAN; PARASITE EXAMINATION; PARASITEMIA; POLYMERASE CHAIN REACTION; SEROLOGY; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, PROTOZOAN; BLOOD; CHAGAS DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICE; MICE, INBRED BALB C; NITROIMIDAZOLES; POLYMERASE CHAIN REACTION; SEROLOGIC TESTS; TREATMENT OUTCOME; TRYPANOSOMA CRUZI;

EID: 44449142382     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn092     Document Type: Article

References (45)

1. World Health Organization. Tropical Disease Research: Progress 2003-2004. Seventeenth Programme Report of the Unicef/UNDD/World Bank/ WHO Special Programme for Research & Training in Tropical Diseases. Programme Report no. 17, Geneva, 2005.
2. Dias JCP. Epidemiology of Chagas disease. In: Chagas Disease (American trypanosomiasis): Its Impact on Transfusion and Clinical Medicine 1992; ISBT, Brazil - SBHH49-80.
3. Urbina JA. Specific treatment of Chagas disease: Current status new developments. Curr Opin Infect Dis 2001; 14: 733-41.
4. Segura MA, Molina RE, MA Basombrio. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment. Mem Inst Oswaldo Cruz 1994; 89: 213-6.
5. Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 1962; 4: 389-96.
6. Andrade SG, Stocker-Guerret S, Pimentel AS et al. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi under specific chemotherapy. Mem Inst Oswaldo Cruz 1991; 86 187-200.
7. Maldonado RA, Molina J, Payares G et al. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chaga's disease. Antimicrob Agents Chemother 1993; 37: 1353-9.
8. Michailowsky V, Murta SM, Carvalho-Oliveira L et al. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant stain of Trypanosoma cruzi. Antimicrob Agenst Chemother 1998; 42: 2549-56.
9. Toledo MJO, Guilherme AL, da Silva JC et al. Trypanosoma cruzi. chemotherapy with benznidazole in mice inoculated with strains from Parana state and from different endemic areas of Brzil. Rev Inst Med Trop Sao Paulo 1997; 39: 283-90.
10. Toledo MJO, Bahia MT, Carneiro CM et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother 2003; 47: 223-30.
11. Urbina J, Payares AG, Sanoja C et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agenst 2003; 21 39-48.
12. Veloso VM, Carneiro CM, Toledo MJO et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz 2001; 96: 1005-11.
13. Andrade SG, Magalhães JB, Pontes AL et al. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull World Health Organ 1985; 63: 721-6.
14. Andrade SG, Silva CR, Santiago CMG et al. Therapeutic action of MK-436 (2,5-nitroimidazole) on Trypanosoma cruzi infections in mice: A parasitological, serological, histopathological, and ultrastructural study. Bull World Health Organ 1987; 65: 625-33.
15. Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 1987; 81: 755-9.
16. Krettli AL, Brener Z. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol 1982; 128: 2009-12.
17. Molina J, Martins-Filho O, Brener Z et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunonocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000; 44: 150-5.
18. Campos RF, Magalhães JB, Reis EA et al. Sensitivity of polymerase chain reaction for detection of known aliquots of Trypanosoma cruzi in the blood of mice: An in vitro study. Rev Soc Bras Med Trop 2002; 35: 487-90.
19. Camandaroba ELP, Reis EG, Gonçalves MS. Trypanosoma cruzi: susceptibilidade to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 2003; 34 Suppl 2: 201-9.
20. Miyamoto CT, Gomes ML, Marangon AV et al. Trypanosoma cruzi: sensitivity of the polymerase chain reaction for detecting the parasite in the blood of mice infected with different clonal genotypes. Exp Parasitol 2006; 112: 198-201.
21. Garzoni LR, Waghabi MC, Baptista MM et al. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004; 23: 286-90.
22. Corrales M, Cardozo R, Segura MA et al. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother 2005; 49: 1556-60.
23. Toledo MJO, Lana M, Carneiro CM et al. Impact of Trypanosoma cruzi clonal evolution on its biological properties in mice. Exp Parasitol 2002; 100: 161-72.
24. Toledo MJO, Bahia MT, Veloso VM et al. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. J Antimicrob Chemother 2004; 53: 1045-53.
25. Tibayrenc M, Ward P, Moya A et al. Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. Proc Natl Acad Sci USA 1986; 83: 115-9.
26. Tibayrenc M, Breniére SF. Trypanosoma cruzi: Major clones rather than principal zymodemes. Mem Inst Oswaldo Cruz 1988; 83 Suppl 1: 249-55.
27. Laurent JP, Barnabe C, Quesney V et al. Impact of clonal evolution on the biological diversity of Trypanosoma cruzi. Parasitology 1997; 114 Suppl 3: 213-8.
28. Pinto AS, Lana M, Bastrenta C et al. Compared vectorial transmissibility of pure and mixed clonal genotypes of Trypanosoma cruzi in Triatoma infestans. Parasitol Res 1998; 84 348-53.
29. Revollo S, Oury B, Laurent JP et al. Trypanosoma cruzi: Impact of clonal evolution of the parasite on its biological and medical properties. Exp Parasitol 1998; 89: 30-9.
30. Pinto AS, Lana M, Britto C et al. Experimental Typanosoma cruzi biclonal infection in Triatoma infestans: Detection of distinct clonal genotypes using kinetoplast DNA probes. Int J Parasitol 2000; 30: 843-8.
31. Franco DJ, Vago AR, Chiari E et al. Trypanosoma cruzi: Mixture of two populations can modify virulence and tissue tropism in rat. Exp Parasitol 2003; 104: 54-61.
32. Martins HR, Toledo MJO, Veloso VM et al. Trypanosoma cruzi: Impact of dual-clone infections on parasite biological properties in BALB/c mice. Exp Parasitol 2006: 112: 237-46.
33. Martins HR, Silva RM, Valadares HM et al. Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi. Antimicrob Agents Chemother 2007; 51: 3282-9.
34. Lana M, Pinto AS, Bastrenta B et al. Trypanosoma cruzi: infectivity of clonal genotypes infections in acute and chronic phases in mice. Exp Parasitol 2000; 96: 61-6.
35. Anonymous. Recommendations from a Satellite Meeting. Mem Inst Oswaldo Cruz 1999; 94 Suppl 1: 429-32.
36. Avila HA, Sigman DS, Cohen LM et al. Polymerase chain reaction amplification at Trypanasoma cruzi kinetoplast minicircle DNA isolated from whole blood lysates: Diagnosis of chronic Chagas's disease. Parasitology 1991; 48: 222.
37. Gomes ML, Macedo AM, Vago AR et al. Trypanosoma cruzi: optimization of polymerase chain reaction for detection in human blood. Exp Parasitol 1998; 88: 28-33.
38. Voller A, Bidwell DE, Bartlett A. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bull World Health Organ 1976; 53 55-65.
39. Cordeiro F-D, Martins-Filho OA, Costa Rocha MO et al. Anti- Trypanosoma cruzi immunoglobulin G1 can be useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diagn Lab Immunol 2001; 20018: 112-8.
40. Martins-Filho OA, Pereira ME, Carvalho JF et al. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clin Diagn Lab Immunol 1995; 2: 569-73.
41. Andrade LO, Machado CR, Chiari E et al. Differential tissue distribution of diverse clones of Trypanosoma cruzi in infected mice. Mol Biochem Parasitol 1999; 100: 163-72.
42. Garcia SC, Ramos O, Senra JF et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decrease cardiac alterations. Antimicrob Agents Chemother 2005; 49: 1521-8.
43. Guedes PM, Veloso VM, Tafuri WL et al. The dog as model for chemotherphy of the Chagas' disease. Acta Trop 2002; 84: 9-17.
44. Nitz N, Gomes C, Cassia RA et al. Heritable integration of kDNA minicircle sequence from Trypanosoma cruzi into the avian genome: insights into human Chagas disease. Cell 2004; 118: 175-86.
45. Teixeira AR, Arganaraz ER, Freitas LH et al. Possible integration of Trypanosoma cruzi kDNA minicircles into the host cell genome by infection. Mutat Res 1994; 305: 197-209.